Drugs / ceperognastat
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05749848 | Feb → Apr 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04392271 | Aug → Oct 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04106206 | Oct 2019 → Feb 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03944031 | May 2019 → Feb 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03819270 | Feb → Jun 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05063539 | Sep 2021 → Jul 2024 | Alzheimer disease | Eli Lilly and Company | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ceperognastat | “To evaluate the efficacy and safety of the potent oral OGA inhibitor ceperognastat in early symptomatic Alzheimer disease (AD).” PMID 42441396 ↗ Jul 2026 |
| Known as | LY3372689 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03819270 ↗ |
| Modality | Small molecule | — CHEMBL5095251 ↗ |
| Route | Oral | “Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods” NCT03819270 ↗ |